In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations

Antiviral Therapy

Volumn 14, Issue 4, 2009, Pages 597-602

  Goubard, Armelle ^a,b   Clavel, François ^a,b   Mammano, Fabrizio ^a,b,c   Labrosse, Béatrice ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ENFUVIRTIDE; VALINE; VIRUS ENVELOPE PROTEIN; GLYCOPROTEIN GP 41; PEPTIDE FRAGMENT;

AMINO ACID SEQUENCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; ARTIFICIAL SELECTION; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENE STRUCTURE; GENETIC VARIABILITY; HEPTAD REPEAT REGION 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SALVAGE THERAPY; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; DRUG EFFECT; GENETIC RECOMBINATION; GENETICS; MUTATION; PROTEIN TERTIARY STRUCTURE;

DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MUTATION; PEPTIDE FRAGMENTS; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; RECOMBINATION, GENETIC;

EID: 68549135071     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280:1884-1888.
2. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387:426-430.
3. Melikyan GB, Markoryan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 2000; 151:413-423.
4. Chen CH, Matthews TJ, Mcdanal CB, Bolognesi DP, Greenbe ML. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol 1995; 69:3371-3777.
5. Greenberg M, Cammack N, Salgo M, Smiley L. HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol 2004; 14:321-337.
6. Sista P, Melby T, Greenberg ML, et al. Characterization of baselined and treatment-emergent resistance to T-20 (enfuvirtide) observed in Phase II clinical trials: substitutions in gp41 amino acids 36-45 and enfuvirtide susceptibility of virus isolates. Antivir Ther 2002; 7 Suppl 1: S16.
7. Lu J, Deeks SG, Hoh R, et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 2006; 43:60-64.
8. Labrosse B, Morand-Joubert L, Goubard A, et al. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 2006; 80:8807-8819.
9. Ray N, Harrison JE, Blackburn LA, Martin JN, Deeks SG, Doms RW. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J Virol 2007; 81:3240-3250.
10. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41 - derived inhibitory peptides. J Virol 1998; 72:986-993.
11. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-1905.
12. Chinnadurai R, Rajan D, Munch J, Kirchhoff F. Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. J Virol 2007; 81:6563-6572.
13. Eggink D, Baldwin CE, Deng Y, et al. Selection of T1249- resistant human immunodeficiency virus type 1 variants. J Virol 2008; 82:6678-6688.
14. Labrosse B, Labernardiere JL, Dam E, et al. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J Virol 2003; 77:1610-1613.
15. Chou T-C. The median effect principle and the combination index for quantitation of synergism and antagonism. In Chou T-C, Rideout DC (Editors). Synergism and antagonism in chemotherapy. San Diego: Academic Press 1991; pp. 61-102.
16. Jenwitheesuk E, Samudrala, R, Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-rersistant HIV-1 gp41 hairpin structure. Antivir Ther 2005; 10:893-900.
17. Xu L, Pozniak A, Wildfire A, et al. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005; 49:1113-1119.
18. Baldwin CE, Sanders RW, Deng Y, et al. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol 2004; 78:12428-12437.
19. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct- regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001; 75:8605-8614.
20. Heil ML, Decker JM, Sfakianos JN, Shaw GM, Hunter E, Derdeyn CA. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J Virol 2004; 78:7582-7589.
21. Reeves JD, Gallo SA, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A 2002; 99:16249-16254.
22. Reeves JD, Miamidian JL, Biscone MJ, et al. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol 2004; 78:5476-5485.
23. Platt EJ, Durnin JP, Kabat D. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J Virol 2005; 79:4347-4356.
24. Baldwin C, Berkhout B. HIV-1 drug-resistance and drug-dependence. Retrovirology 2007; 4:78.